Cargando…

Major adverse kidney events predict reduced survival in ventricular assist device supported patients

AIMS: There is limited data describing major adverse kidney events (MAKE) in patients supported with ventricular assist devices (VAD). We aim to describe the association between MAKE and survival, risk factors for MAKE, and renal trajectory in VAD supported patients. METHODS AND RESULTS: We conducte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barua, Sumita, Conte, Sean M., Cherrett, Callum, Kearney, Katherine L., Robson, Desiree, Bragg, Christopher, Macdonald, Peter S., Muthiah, Kavitha, Hayward, Christopher S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682875/ https://www.ncbi.nlm.nih.gov/pubmed/37712126 http://dx.doi.org/10.1002/ehf2.14533

Ejemplares similares

Value of Renal Histology in Predicting Cardiorenal Outcomes in Heart Transplant–listed Patients
por: Barua, Sumita, et al.
Publicado: (2022)

The use of eculizumab as a bridge to retransplantation for chronic antibody-mediated rejection in a heart transplant recipient: a case report
por: Kearney, Katherine, et al.
Publicado: (2021)

Intermittent Papillary Muscle Suction: A Rare Cause of Left Ventricular Assist Device Low Flow
por: Deveza, Ricardo C., et al.
Publicado: (2021)

Choosing Between Left Ventricular Assist Devices and Biventricular Assist Devices
por: Shehab, Sajad, et al.
Publicado: (2019)

Too Much Too Soon? The Catch-22 of Catching COVID-19
por: Lo, P.K., et al.
Publicado: (2022)

Pre-Transplant Left Ventricular Geometry and Major Adverse Cardiovascular Events After Kidney Transplantation
por: Malyala, Rohit, et al.
Publicado: (2019)

Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
por: Yasuda, Masakazu, et al.
Publicado: (2016)

Trends, Perioperative Adverse Events, and Survival of Patients With Left Ventricular Assist Devices Undergoing Noncardiac Surgery
por: Mentias, Amgad, et al.
Publicado: (2020)

Angiopoietin‐2 and hemocompatibility‐related adverse events during percutaneous left ventricular assist device supports
por: Imamura, Teruhiko, et al.
Publicado: (2020)

Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients
por: Cehic, Matthew G., et al.
Publicado: (2019)

Management of the arrhythmic manifestations of cardiac sarcoidosis
por: Cherrett, Callum, et al.
Publicado: (2023)

When logic fails
por: Phan, Justin, et al.
Publicado: (2023)

Dynamic changes of monocytes subsets predict major adverse cardiovascular events and left ventricular function after STEMI
por: Boidin, Maxime, et al.
Publicado: (2023)

Identifying Temporal Relationships Between In‐Hospital Adverse Events After Implantation of Durable Left Ventricular Assist Devices
por: Kilic, Arman, et al.
Publicado: (2020)

Adverse Events of Percutaneous Microaxial Left Ventricular Assist Devices—A Retrospective, Single-Centre Cohort Study
por: Zaiser, Anna S., et al.
Publicado: (2021)

Adverse events with HeartMate-3 Left ventricular assist device: Results from the Manufacturer and User Facility Device Experience (MAUDE) database
por: Heaton, Joseph N., et al.
Publicado: (2021)

Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices
por: Pausch, Jonas, et al.
Publicado: (2023)

Xerosis and pruritus as major EGFRI-associated adverse events
por: Clabbers, Julia M. K., et al.
Publicado: (2015)

Implementation of adverse event reporting for medical devices, India
por: Shukla, Shatrunajay, et al.
Publicado: (2020)

Prognostic Value of Natriuretic Peptides for All-Cause Mortality, Right Ventricular Failure, Major Adverse Events, and Myocardial Recovery in Advanced Heart Failure Patients Receiving a Left Ventricular Assist Device: A Systematic Review
por: Janssen, Eva, et al.
Publicado: (2021)

Association Between Wearable Device–Based Measures of Physical Frailty and Major Adverse Events Following Lower Extremity Revascularization
por: Najafi, Bijan, et al.
Publicado: (2020)

Atrial high-rate episodes predict major adverse cardio/cerebrovascular events in patients with cardiac implantable electrical devices
por: Chen, Ju-Yi, et al.
Publicado: (2021)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
por: Kavanagh, Kevin T, et al.
Publicado: (2019)

Prognostic Implications of Left Ventricular Dyssynchrony for Major Adverse Cardiovascular Events in Asymptomatic Women and Men: The Multi‐Ethnic Study of Atherosclerosis
por: Sharma, Ravi K., et al.
Publicado: (2014)

Left Ventricular Geometry and Replacement Fibrosis Detected by cMRI Are Associated with Major Adverse Cardiovascular Events in Nonischemic Dilated Cardiomyopathy
por: Cojan-Minzat, Bianca Olivia, et al.
Publicado: (2020)

Predictors of major adverse events and complications after ventricular septal defects surgical closure in children less than 10 kg
por: Abdelrehim, Ayman R., et al.
Publicado: (2022)

Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device
por: McClane, Nathan, et al.
Publicado: (2018)

Adherence to Guideline‐Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease
por: Armstrong, Ehrin J., et al.
Publicado: (2014)

Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial
por: Raven, Lisa Mary, et al.
Publicado: (2023)

THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design
por: Raven, Lisa M, et al.
Publicado: (2023)

Comparison of continuous‐flow ventricular assist device therapy with intensive medical therapy in fixed pulmonary hypertension secondary to advanced left heart failure
por: Kumarasinghe, Gayathri, et al.
Publicado: (2018)

Sarcoidosis: comprehensive CMR evaluation and major adverse cardiac events
por: Higgins, Angela Y, et al.
Publicado: (2016)

Low Prevalance of Major Events Adverse to Exercise Stress Echocardiography
por: Andrade, Stephanie Macedo, et al.
Publicado: (2016)

Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
por: Mal, Kheraj, et al.
Publicado: (2020)

Prediabetes as a risk factor for major adverse cardiovascular events
por: Mando, Ramy, et al.
Publicado: (2021)

Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events
por: Gaist, David, et al.
Publicado: (2022)

Comparison of HEAR and HEART Scores for Major Adverse Cardiovascular Events
por: Uyan, Umut
Publicado: (2023)

Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Intraocular devices associated adverse events reporting system in India
por: Kalaiselvan, Vivekanandan, et al.
Publicado: (2020)

Reporting of Cardiovascular Medical Device Adverse Events to Pharmaceuticals and Medical Devices Agency, Japan()
por: Handa, Nobuhiro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0hh6e5i70fj13pslatgrl5sb53